A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL

CD19 is ubiquitously expressed on chronic lymphocytic leukemia (CLL) cells and is therefore an attractive candidate for antibody targeting. XmAb5574 (aka MOR00208) is a novel humanized CD19 monoclonal antibody with an engineered Fc region to enhance Fcγ receptor binding affinity. Here we report resu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Woyach, Jennifer A., Awan, Farrukh, Flinn, Ian W., Berdeja, Jesus G., Wiley, Elizabeth, Mansoor, Sharmeen, Huang, Ying, Lozanski, Gerard, Foster, Paul A., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4256907/
https://ncbi.nlm.nih.gov/pubmed/25301708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-08-593269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados